Category: EQS Newswire

EQS via SeaPRwire.com / 16/01/2026 / 11:05 UTC+8 Accelerated overseas strategy as an integral part of brand transformation (Hong Kong, Bangkok, 16 January 2026) Chow Tai Fook Jewellery Group Limited ("Chow Tai Fook Jewellery Group", the "Group" or the "Company"; SEHK stock code: 1929), the global Chinese luxury group built on a nearly-century old legacy of trust and innovation, announces the opening of a key strategic store in Bangkok, Thailand, within the iconic Siam Paragon, as well as the appointment of acclaimed Chinese actor Yang Yang as its Global Brand Ambassador. These initiatives mark significant milestones in the Group’s brand transformation journey as it redefines global luxury through Chinese craftmanship and artistry. The Group, which operates over 5,000 stores globally with a market capitalisation of approximately HK$122 billion, equivalent to US$16 billion, (as of 31 December 2025), is strengthening its presence in luxury destinations across international markets as part of its brand transformation. The new store at a Southeast Asian luxury retail landmark showcases Chow Tai Fook Jewellery’s blend of modern sophistication with the richness imbued by cultural heritage. In addition, the appointment of Global Brand Ambassador Yang Yang reflects the commitment to engaging new audiences and deepening emotional resonance with overseas consumers. Yang Yang, a renowned globally recognised Chinese actor, is set to strengthen the brand’s presence in key international markets, positioning it as a modern, elegant embodiment of Chinese luxury on the world stage. A New Expression of Heritage and Modern Luxury The new Siam Paragon store features the brand’s iconic “Chow Tai Fook Timeless Red” throughout. The space celebrates the beauty of Chinese craftsmanship and artistry with the use of refined materials and thoughtful lighting that create a warm, gallery-like ambience. To build connections and emotional resonance, the Group is introducing a selection of Thai-exclusive pieces that honour local culture. “As we advance our dynamic brand transformation journey, curating exceptional retail experiences in international markets is pivotal in Chow Tai Fook Jewellery’s overseas expansion strategy. This expansion is part of our ambition to establish Chow Tai Fook Jewellery as a leading force in global luxury, while reinforcing our legacy of innovation, excellence, and cultural resonance,” said Ms Sonia Cheng, Vice-chairman of Chow Tai Fook Jewellery Group. She further remarked: “Another key aspect of our strategic vision is the appointment of Yang Yang as our Global Brand Ambassador. Through this alliance, we will cultivate a refined and contemporary identity for a Chinese luxury brand on the world stage.” Accelerating Global Reach to Redefine Luxury Across Borders Chow Tai Fook Jewellery’s international business expansion is guided by a two-pronged approach: revitalising key existing markets and expanding into high-potential new territories for sustainable growth. With around 60 points of sales across international markets in 1HFY2026 (April to September 2025), the Group’s retail sales in Other Markets segment (including China duty-free) grew nearly 17% year-on-year. The opening of the Siam Paragon store follows the debut of the Group’s first newly designed store in Southeast Asia, which opened at Singapore Changi Airport in November 2025. Building on this momentum, Chow Tai Fook Jewellery is set to further expand its international retail network, with plans to open its first store in Australia and an additional store in Canada by the end of June 2026. The Group also intends to expand into the Middle East market within two years. Redefining Global Luxury Through Chinese Artistry In celebration of its 95th anniversary, the Group embarked on a brand transformation journey in 2024 to redefine global luxury. By blending heritage with contemporary iconic designs, the Group showcases the beauty of China to the world through exquisite jewellery that honours tradition while embracing modern elegance. Chow Tai Fook Jewellery is the first Chinese jewellery brand to appoint a Creative Director with international perspectives and exposure, underscoring its commitment to innovative design and narrative-driven branding. Led by Creative Director of High Jewellery, Nicholas Lieou, the Group introduced its signature collections, including the CTF Rouge and CTF Joie Collections. ### Chow Tai Fook Jewellery Group Limited Since its founding in 1929, CHOW TAI FOOK, the flagship brand of Chow Tai Fook Jewellery Group, has been celebrated for its bold designs and meticulous attention to detail. Our commitment to innovation and craftsmanship has made us synonymous with excellence, value, and authenticity. As the global Chinese luxury group, we blend contemporary designs with traditional techniques to create timeless pieces. Each collection reflects our customers' stories and lives, celebrating their special moments. We aspire to inspire and captivate generations to come, weaving the story of CHOW TAI FOOK into their own. Our brand portfolio includes the iconic CHOW TAI FOOK flagship brand, HEARTS ON FIRE, ENZO, and MONOLOGUE, offering a wide variety of products that also includes an expanding range of cutting-edge IP collaborations. With over 5,000 stores worldwide, we offer a seamless client journey across all touchpoints that includes a network across China as well as a growing number of global locations. Chow Tai Fook Jewellery Group Limited (SEHK: 1929) has been listed on the Main Board of the Hong Kong Stock Exchange since December 2011. We are committed to delivering sustainable long-term value for our stakeholders by continually enhancing earnings quality and driving higher value growth. Media Enquiries: Chow Tai Fook Jewellery Group Limited Haide Ng Associate Director, Corporate Communications Tel: (852) 3115 4402 Email: haideng@chowtaifook.com Acky Chan Senior Manager, Corporate Communications Tel: (852) 3115 4403 Email: ackychan@chowtaifook.com 16/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 16/01/2026 / 09:17 UTC+8 Kuala Lumpur– AIMS is pleased to announce an official partnership with the Lamborghini Brand and its winery. This collaboration represents not only a powerful alliance between two leading brands from distinct fields, but also a dedicated effort to transcend traditional industry boundaries, creating an unprecedented platform of excellence for traders and brand enthusiasts across the Asia-Pacific region and globally. Lamborghini is not only an icon of ultimate automotive craftsmanship but has also extended its pursuit of luxury and quality into the world of wine. The spirit of resilience, excellence, and breakthrough embodied by its founder, Mr. Ferruccio Lamborghini, has been ingrained in the winery since its establishment in 1968. Faithfully continue Lamborghini's relentless pursuit of perfection and channeling the fighting spirit symbolized by the iconic Taurus emblem. "We are truly honored to enter into this partnership," mentioned by Aaron Chang, CEO of AIMS. "This goes far beyond a commercial linkage; it is a profound alignment of brand philosophies. AIMS is committed to providing users with exceptional and efficient service experience, empowering them to continually push boundaries and pursue the 'extraordinary' in their trading journey. This resonates perfectly with the Lamborghini founder's ethos of constantly challenging limits and pursuing perfection. We look forward to working together to open new doors for our clients, leading them toward greater achievements and unique experiences." "This partnership sets a new benchmark where elite trading services converge with legendary Italian luxury," said Mr. Stanley Ng, Principal Consultant & Advisor for the Lamborghini Brand and Winery in Southeast Asia. "We are confident that AIMS distinguished market presence and influence will further elevate the brand experience for connoisseurs throughout the region." This partnership marks a strategic step in AIMS’s global expansion, further solidifying its leadership in integrating high-end lifestyle offerings with advanced trading platforms. Moving forward, both parties will jointly explore greater cross-sector value, providing high-end clients with a new dimension of experience that combines luxurious taste with excellent performance. About AIMS AIMS is a brand with an 11-year industry heritage and a trusted financial broker for institutional and individual traders worldwide. With a global presence spanning more than 21 countries and regions, the broker is renowned for its high-performance trading platforms, highly competitive spreads, and client-centric service philosophy, continuously driving development and innovation in the global trading industry. For more information about Aims, please visit www.aimsfx.com or follow their social media accounts on Facebook, Instagram and Tiktok. Media Contact: Benson Low, AIMS Email: media@aimsfx.com Website: www.aimsfx.com 16/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 15/01/2026 / 12:50 UTC+8 January 14, 2026 — WuXi XDC has issued a positive profit alert for fiscal 2025 and announced a cash tender offer for BioDlink, whose shares were suspended from trading at 9am on December 29 pending details of the bid. The alert underscores the ADC CRDMO leader’s strong performance: it forecasts 45% year-on-year revenue growth in 2025, alongside over 70% gross profit growth and more than 45% growth in adjusted net profit (excluding interest income and expenses). Stripping out exchange rate fluctuations, adjusted net profit growth is projected to hit 65%. A pioneer in the ADC CRDMO space, WuXi XDC has driven synergistic growth through organic expansion and strategic acquisitions amid strong business momentum. The BioDlink acquisition will boost its operational capacity in China, expand production scale, enhance support for biotech firms via value-added services, broaden its project portfolio and customer base, and reinforce its leading position in the ADC CDMO sector. "Capital for time": WuXi XDC targets CDMO capacity bottlenecks The bioconjugate drug industry has reached a commercial inflection point as clinical pipelines expand, widening the capacity gap. Public data shows 21 ADC drugs had been approved globally by end-December 2025. Emerging classes such as AOCs, RDCs and PDCs are advancing rapidly with robust late-stage pipelines, emerging as new growth drivers in biopharma. Against accelerating global bioconjugate commercialisation, insufficient capacity has become a major constraint for CDMOs. Rapid pipeline expansion and upcoming commercial demand have made "capacity delivery capability" a core competitive advantage and key metric for investors assessing CDMO growth potential. For leading CDMOs, the approach to resolving capacity bottlenecks directly shapes market influence. Building new production lines—from site selection and construction to certification—typically takes three to five years, too slow to keep pace with surging bioconjugate commercial demand. WuXi XDC’s proactive strategy of acquiring existing facilities, using efficient capital operations to capture market opportunities, stands out as optimal in the sector. The BioDlink deal aligns with this logic, enabling rapid capacity expansion via external integration and ensuring steady performance growth. Building on strengths: Tech platforms and talent drive growth WuXi XDC leads the industry with advanced conjugation and payload-linker technologies, and extensive bioconjugate drug development experience. It has rolled out innovative platforms including WuXiDARx™, dual-payload conjugation, X-LinC linker, and WuXiTecan-1/2 payload-linker technologies. To meet global customers’ diverse ordering needs and complex R&D requirements, it adopts a two-pronged "independent R&D plus external collaboration" strategy to build an integrated technology platform. This enriches technical reserves, boosts front-end R&D pipeline generation, and strengthens its R&D leadership. Talent is critical to the bioconjugate CDMO sector, but rapid industry growth has outpaced professional talent supply, a key growth constraint. WuXi XDC has long prioritised talent development; its workforce exceeded 2,600 by end-2025. The expanded professional team has formed a talent cluster, underpinning long-term growth. Riding the wave: WuXi XDC’s global capacity push Data from PharmaCube’s NextPharma shows China’s innovative drug overseas licensing transactions hit $135.655bn in 2025, including $7bn in upfront payments across 157 deals—far outstripping 2024’s $51.9bn and 94 transactions. Overseas licensing has seen explosive growth, with upfront payments and total volume at record highs. As a key bioconjugate segment, ADCs are a focus for global capital. WuXi XDC has delivered standout performance here, with steady post-listing revenue growth underscoring both the bioconjugate CDMO track’s potential and the company’s core competitiveness. Sustained business growth has made capacity expansion a key driver of high growth. By end-December 2025, WuXi XDC had worked with over 640 global customers on 252 iCMC projects. It also holds 18 PPQ projects and one commercial project, with nearly 1,000 production batches of drug substance (DS) and drug product (DP). These figures highlight strong market expansion and capacity deployment, reflecting robust demand for its services. The industry’s capacity shortage is both quantitative and structural, marked by a lack of "high-quality, integrated" capacity. Hundreds of ADCs globally are in active clinical phases, creating strong demand for commercial capacity. Meanwhile, bioconjugates’ complex production processes, high industry barriers and long supply chains have further widened the gap. Against this backdrop, WuXi XDC has established capacity in Wuxi, Jiangyin, Hefei (China) and Singapore. This global network meets global customers’ local production needs, improves operational efficiency via coordinated capacity allocation, strengthens its bioconjugate CDMO lead, and allows it to fully capture industry growth opportunities. Table: WuXi XDC’s capacity layout as of end-2025 Layout Capacity Wuxi Site XBCM1(Conjugation DS): 5-500L per batch XBCM2 L1&L2(Dual-function lines for antibody and conjugation DS): 50L to 2000L per batch for monoclonal antibody intermediates or up to 2000L of DS per batch Conjugation DP Lines: XDP1: annual capacity of 3 million vials XDP2: annual capacity of 5 million vials XDP3: annual capacity of 7 million vials XDP5: annual capacity of 12 million vials, expected to GMP release in 2027 XDP6: annual capacity of 10 million vials, expected to GMP release by late 2027 / early 2028 XPLM1 (Kilogram-scale payload-linker Line, business from former Changzhou site is being gradually transferred to Wuxi site) Singapore Site XBCM3(Dual-function line for antibody and conjugation DS): 50L to 2000L per batch for monoclonal antibody intermediates or up to 2000L of DS per batch, expected to GMP release in 2026 XBCM4(Conjugation DS): up to 500L per batch, expected to GMP release in 2026 XDP4(Conjugation DP): annual capacity of 8 million vials, expected to be operational in 2026 Jiangyin Site Integrated Commercial Manufacturing Site: serves as a nearby expansion for Wuxi site, including large-scale commercial small molecule production and conjugation production workshops. Hefei Site Non-GMP Manufacturing: Peptide annual capacity of ~600 batches, ~30kg GMP Manufacturing: Peptide annual capacity of ~200 batches, ~10kg Data source: Company filings WuXi XDC to sustain capacity expansion drive Looking ahead, WuXi XDC will continue to advance overseas capacity expansion steadily and proactively, further entrenching its global leadership in the bioconjugate CDMO sector. In September 2025, the company completed a $350m refinancing, leveraging strong performance and industry reputation. Combined with a previous $200m credit facility and operational reserves, it has built a sufficient capital pool to support global capacity expansion. Backed by solid capital and mature expansion experience, WuXi XDC will pursue overseas capacity growth at an "active yet prudent" pace. It is evaluating global expansion opportunities to optimise its production network—moves that will enable local delivery, deepen penetration in the global bioconjugate CDMO sector, and reinforce its industry lead. Outlook WuXi XDC’s accelerated capacity deployment mirrors the rapid growth of ADC and other bioconjugate industries, driving the CDMO sector into a golden growth period. Frost & Sullivan data shows the global ADC drug market reached $17.2bn in 2025, with a 30.6% compound annual growth rate (CAGR) from 2023 to 2032, and is set to exceed $115.1bn by 2032. The global ADC outsourcing market is also growing strongly, projected to hit $11bn by 2030 with a 28.4% CAGR from 2022 to 2030. High growth in both sectors offers ample room for CDMO expansion. Capacity shortages are a phased challenge in the booming bioconjugate CDMO industry, unlikely to be fully resolved short-term. Over the medium to long term, however, new capacity from leading players and rising industry concentration will ease the supply-demand imbalance. WuXi XDC’s early focus on "acquisition plus expansion"—backed by accurate industry trend judgment—has secured its edge in current capacity competition and positioned it to dominate the future bioconjugate CDMO landscape, leveraging strengths in capacity scale, technical barriers and global reach. Sources 1. Hong Kong Exchanges and Clearing (HKEX) 2. WuXi XDC 3. Frost & Sullivan 4. PharmaCube 5. Insight Database 6. WuXi XDC presentation, 2025 Jefferies London Healthcare Conference 15/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 14/01/2026 / 11:38 UTC+8 PayDo launches its Dedicated C2B Open Banking Collections Ecosystem, a revolutionary platform designed for high-volume merchants. This innovation addresses operational bottlenecks by providing automated reconciliation and real-time tracking for Open Banking transactions, rendering them as reliable and scalable as traditional card payments. London, UK - January 14, 2026 - (SeaPRwire) - PayDo, a globally regulated payment ecosystem, today announced the launch of its innovative dedicated C2B Open Banking Collections Account. This new initiative is designed to transform how high-volume online businesses handle direct bank payments, effectively eliminating the operational chaos and accounting bottlenecks that have historically hindered the scalability of Open Banking. Photo Courtesy of PayDo The new solution addresses a critical market gap where traditional banking infrastructure treats Open Banking payments as generic, non-descript credit transfers. For e-commerce merchants processing thousands of daily transactions, this previously created a manual reconciliation nightmare. PayDo’s solution reimagines this relationship by providing a unique, managed account environment. Within this ecosystem, every transaction is automatically tagged, tracked, and reconciled in real-time, mirroring the efficiency and clarity of card payments while retaining the cost and speed benefits of Open Banking. “Solving fraud by introducing confirmation of payment receipt instead of initiation was the first step, but to truly unlock Open Banking for commerce, we had to solve for scale,” said Serhii Zakharov, CEO & Founder of PayDo. “Our dedicated C2B Collections Account is engineered to treat direct bank payments with the same efficiency, reporting, and reliability as traditional card acquirers. We’ve moved the needle from making Open Banking ‘possible’ to making it ‘operationally excellent’ for businesses that process millions in volume. This is how you turn a promising rail into a foundational one.” Data from early implementations highlights the system’s robust capacity, with the infrastructure engineered to process immense volumes seamlessly—transforming over 100,000 daily transactions from a logistical challenge into a manageable operational flow. This capability enables merchants to achieve faster settlement times and lower transaction costs without compromising the operational oversight necessary for large-scale commerce. Merchants and online businesses can integrate the C2B Collections Account directly into their existing payment infrastructure, thereby streamlining their reconciliation processes immediately. Visit the PayDo website (www.paydo.com) to learn more about the subject of the press release. About PayDo PayDo is a globally regulated payment ecosystem that consolidates multi-currency accounts, global acquiring, e-wallet checkout, and innovative Open Banking solutions into a single unified platform. Founded in 2017, the company provides online businesses with a comprehensive suite of financial tools designed to simplify cross-border payments and streamline operations. With a focus on transforming complex financial challenges into scalable solutions, PayDo processes over €5 billion annually. The company is recognized for its commitment to security and innovation, offering infrastructure that bridges the gap between traditional banking and modern digital commerce for clients worldwide. PayDo’s Founder and CEO Serhii Zakharov is a published fintech thought leader, Member of the Forbes Technology Council and The Payment Association’s Payment Leaders Group. Serhii has pioneered a string of groundbreaking innovations such as Non-Redirect E-Wallet, Open Banking Collections Account and many others, all part of a unique Unified Ecosystem powered by PayDo. Contact Information Organization: PayDo Contact: Artem Trofymenko Email: artem.tr@paydo.com Website: www.paydo.com 14/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 14/01/2026 / 10:06 UTC+8 London, UK - January 14, 2026 - (SeaPRwire) - Payroll just became more intelligent. Mercans introduced an AI-powered payroll validation tool designed to improve accuracy, compliance, and operational efficiency. The solution transforms payroll from a routine administrative task into a strategic, insight-driven function. Unlike traditional payroll validation tools that generate generic error flags, the platform provides clear explanations and actionable guidance whenever anomalies are detected. It reviews historical payroll data to detect missing information, unexpected variances, or duplicate entries. These insights allow HR and finance teams to resolve issues quickly, saving both time and resources. Practical Intelligence for Every Payroll Cycle The platform combines artificial intelligence with rule-based validation to provide a proactive solution that integrates smoothly into existing payroll processes. Teams can anticipate potential issues and reduce operational risks before they escalate. Users receive insights in a human-readable format, keeping decisions transparent and accountable. "Our goal focuses on transforming payroll into more than an administrative function. Embedding AI into everyday processes strengthens compliance, accuracy, and operational confidence," said Tatjana Domovits, Group CEO of Mercans. Security and Global Compliance at Its Core Privacy and security guide the platform's design. It processes only anonymized identifiers and automatically scrubs sensitive information, thereby complying fully with international data protection standards. These measures enable organizations to utilize AI-driven insights while maintaining employee confidentiality. Supporting operations in over 160 countries, the system maintains consistency and regulatory compliance across regions. Automated routines and intelligent analysis reduce repetitive audits, making global payroll management more efficient. "We focused on creating AI that is transparent and actionable. Teams can see how the system reaches conclusions, giving them confidence to make informed decisions in each payroll cycle," said Oleg Denysenko, Deputy Head of Engineering. Accessible Technology for All Clients Mercans includes AI-powered payroll validation at no extra charge, reinforcing its goal of providing advanced technology to a wide audience. The tool complements the HR Blizz platform, which combines automation, analytics, and compliance to streamline global payroll operations. Integrating AI into payroll at scale allows businesses to gain deeper insights, prevent errors, and maintain compliance across international operations. The launch marks a significant milestone in payroll management, providing intelligence that enhances operational efficiency. About Mercans Mercans is a leading provider of global payroll technology and compliance solutions. The company helps multinational organizations manage payroll efficiently, accurately, and securely. With a strong focus on technology and client outcomes, Mercans continues to shape the future of payroll management. Contact Information Organization: Mercans Contact: Mohsin Khan Email:mkhan@mercans.com Website: https://mercans.com 14/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 06/01/2026 / 17:29 UTC+8 Today, Concord New Energy Group Limited (CNE Group) is successfully secondary listing on main board of SGX Stock exchange, under the stock code “SEG”. This remarks a key step forward to drawing the blueprint of CNE Group globalization strategy. Concord New Energy Group Limited (CNE) is a Singapore-headquartered company focuses in renewable energy industry nearly two decades, been listed on HKEX mainboard since 2007. CNE is committed always to providing high-quality clean energy and related professional services. Our business has covered development, investment and operation of wind power, photovoltaic (PV) and energy storage assets global wide. Currently, CNE is managing a total equity capacity more than 5GW. Liu Shunxing, Chairman of the board of CNE, said, “Today makes a significant milestone for CNE Group. Our secondary listing on the Singapore Exchange represents a key step in advancing our global business strategy. It reflects our long-term commitment to strengthening corporate governance and actively engaging with international capital markets. Singapore occupies a uniquely strategic position at the intersection of advanced artificial intelligence, next-generation energy systems, and global capital markets. We are honored to become part of Singapore’s capital market and look forward to building long-term, constructive partnerships with both local and international investors. We remain firmly committed to contributing more on the global transition from fossil fuels to clean and renewable energy.” Pol de Win, Head of Global Sales and Origination, SGX Group, give his congratulations to CNE, and said, “As Asia’s most international multi-asset exchange with a strong commitment to transition finance, SGX will offers Concord New Energy Group an international platform to expand its reach to a diverse network of global investors, customers and partners as it advances the transition to cleaner energy.” 06/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 05/01/2026 / 07:00 UTC+8 Home Control（1747.HK）Revamped the Panel of Non-Executive Directors; Market expects Strengthening Agility and Corporate Governance to Support Home Healthcare Business Development (Hong Kong - 5 Jan 2026) Home Control（1747.HK） has recently revamped the Board of directors, merely involving non-executive directors and independent non-executive directors. While the executive directors and the management team were not affected, the Company’s daily operations and business fundamentals remain solid. Market observers have noted that the Board of directors have streamlined from 9 members to 6. The change is expected to improve agility and effectiveness in the long run, enabling better support for the Company’s strategic expansion into home healthcare business and long-term enhancements in corporate governance. Notably, the Company has appointed Mr. Bernard Eng Chuan LIM as an Independent Non-Executive Director, who is a Chartered Accountant (Singapore) and currently serves as the Finance Director of a Singapore-based private investment group. Not long ago, another two Independent Non-Executive Directors Mr. Min YE and Mr. Yi Chung CHEN were newly appointed. Mr. Min YE previously served as Managing Director - Head of International at Moody's Corporation while Mr. Yi Chung CHEN is currently the Chief Operating Officer of a healthcare group. The three new Independent Non-Executive Directors (INEDs) have formed a strong team, fulfilling its responsibility to enhance the Board's oversight, governance, and strategic support functions. The resigning directors include Mr. Alain Perrot, non-executive director and chairman of the Board, as well as independent non-executive directors including Mr. Werner Peter Van Eck, Ms. Keet Yee LAI and Dr. Shou Kang CHEN. These directors were engaged at the earlier stage of Home Control when its core focus was the traditional home control business. Since 2025, Home Control has been actively developing the AIoT-enabled home healthcare ecosystem, it is believed that the change in INEDs as part of a strategic transformation, representing a phased optimisation and reorganisation of the Board structure, with a view to introducing more professionals with expertise in healthcare, capital management and corporate governance. Under the Listing Rules in Hong Kong, companies listed on the main board are required to appoint at least three independent non-executive directors. Regarding the new Board structure of Home Control, the Company has appointed Mr. Bernard Eng Chuan LIM with extensive experience in finance and healthcare-related assets, along with the two previously appointed INEDs, Mr. Min YE and Mr. Yi Chung CHEN. This new composition complies with Hong Kong regulations, providing professional expertise and independent judgement on the business, conducting risk assessment, safeguarding shareholders’ interests and further enhancing the Company’s governance standards. Mr. Bernard Eng Chuan LIM is a Chartered Accountant (Singapore) with over 30 years of experience in senior finance leadership roles across multiple organisations, with experience spanning corporate finance, controllership, governance and strategic planning. He is currently the Finance Director of RB Capital Pte. Ltd. Mr. Lim held senior finance leadership roles across multiple organisations, including serving as Chief Financial Officer of OUE Limited for 10 years. He also served as Chief Financial Officer at Tsao Family Office Pte. Ltd. and as Business Controller (Finance) at Pacific Eagle Real Estate. During his tenure at OUE Limited, Mr. Lim worked on various significant corporate actions, capital markets initiatives and strategic investments. This included OUE Limited’s entry into the healthcare real estate sector through the acquisition of International Healthway Corporation Limited (IHC) , which is a healthcare services and facilities provider with operations across Southeast Asia. Since 2025, Home Control has progressively appointed several directors with background in healthcare and capital markets, including Mr. Min YE and Mr. Yi Chung CHEN who have extensive experience in healthcare, risk management, capital markets and corporate governance. The appointment has further reinforced the Board’s professional judgement and oversight capabilities in support of the Company’s new business direction, laying a solid governance foundation for the expansion of its AIoT-enabled home healthcare ecosystem. Currently, Home Control’s headquarters and principal operating team are based in Singapore, with a stable core management, executive team and operating structure. The newly revamped Board of directors comprises members have experience in serving at Singapore-based and international institutions. Market believes that the new INEDs will achieve effective communication with the core management team and drive continuous steady development of both its established smart home control business and its newly expanded home healthcare operations. File: Home Control（1747.HK）Revamped the Panel of Non-Executive Directors; Market expects Strengthening Agility and Corporate Governance to Support Home Healthcare Business Development 05/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 30/12/2025 / 17:36 UTC+8 [Hong Kong, December 30th, 2025] Uni-Bio Science Group Limited (“Uni-Bio Science Group”, “Uni-Bio” or “the Group”) is pleased to announce the official signing of a tripartite strategic cooperation agreement in Wenzhou, Zhejiang, with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University (“WMU NERC”) and the People's Government of Ouhai District, Wenzhou. The parties also explored the subsequent co-establishment of the "Uni-Bio - WMU Joint Innovation Laboratory for Translational Medicine." This collaboration marks a key step for Uni-Bio in deeply integrating with a national-level research platform and a regional industrial ecosystem. Through a synergistic “government-university-enterprise” model, the three parties will focus on the core regenerative medicine field of growth factors to establish an end-to-end innovation system spanning basic research, clinical translation, and industrial application. This represents a milestone for the Group in consolidating its R&D pipeline and accelerating its strategic execution. （Photo: Strategic cooperation signing ceremony group photo） Focusing on Growth Factor Frontiers, Unleashing “1+1>2” Clinical and Market Potential Growth factors are key signaling molecules that regulate cell proliferation, migration, and tissue repair, representing some of the most transformative bioactive substances in regenerative medicine. Both EGF (Epidermal Growth Factor) and FGF (Fibroblast Growth Factor) have demonstrated significant efficacy across major indications, including wound healing, ophthalmic diseases, and metabolic disorders, underscoring their substantial market potential. Uni-Bio possesses deep expertise in the EGF field, with its flagship products GeneTime® and GeneSoft® achieving large-scale production and nationwide commercial coverage. Concurrently, under the leadership of Academician Li Xiaokun, the WMU NERC has been a global pioneer in FGF drug R&D, having successfully translated several Class I New Drugs - including Recombinant Human Basic Fibroblast Growth Factor - and has accumulated substantial clinical data and authoritative expert consensus in trauma and metabolic diseases. Building on this foundation, the three parties will initiate collaborative research on combined EGF/FGF therapies for key areas, including burns, dermatology, and ophthalmology. The goal is to unlock powerful therapeutic synergies, develop superior combination products and advance delivery systems, set new treatment benchmarks, and establish a leadership position in shaping this multi-billion Yuan sector. Empowered by Academician Leadership & Platform, Creating a Fast Track from R&D to Production The WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. In synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large-Scale Preparation, which focuses on upstream basic research, the Center has built a next-generation growth factor drug pipeline targeting multiple systems such as metabolism and dermatology. Through the ongoing research of Academician Li Xiaokun’s team, the Center has achieved internationally leading breakthroughs in key technologies, including long-acting Modification, targeted delivery, and aerosol inhalation. The planned "Uni-Bio – WMU Joint Innovation Laboratory for Translational Medicine" will conduct in-depth research into the synergistic mechanisms of Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair. It aims to develop novel compound formulations and drug delivery systems targeting conditions such as endocrine diseases represented by non-alcoholic steatohepatitis (NASH), respiratory diseases represented by asthma, as well as bone tissue repair. These diseases affect a large global patient population, yet there remains a significant unmet clinical need for innovative therapies. Through this collaboration, it is expected to address treatment gaps in multiple specific indications, further unlocking clinical and commercial value in the broad chronic disease market. The "Government-University-Enterprise " Trinity, Systematically Strengthening Full-Chain Capabilities This collaboration extends beyond technological synergy to ecosystem co-development. The People's Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the "China Gene Valley," will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization. For Uni-Bio, this tripartite cooperation delivers threefold empowerment: R&D Front: Direct access to the National Engineering Research Center’s source innovation and core technologies, elevating the starting point of R&D. Clinical Front: Collaboration with Wenzhou Medical University’s affiliated hospital network to accelerate clinical validation and indication expansion. Commercialization Front: Leveraging the advanced manufacturing capabilities and regional policy benefits of the China Gene Valley to ensure efficient project implementation and facilitate market access. This strategic partnership is a crucial step in the Group's pursuit of its vision "To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life" Moving forward, the Group will continue to deepen collaborations with national scientific institutions and local governments, driving the translation of more cutting-edge research into clinical and market value. This will further consolidate and enhance its comprehensive competitiveness and leadership in regenerative medicine. End About Uni-Bio Science: Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life. About the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University: The WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. Under the leadership of Chinese Academy of Engineering Academician Li Xiaokun, the Center has long been engaged in foundational research and novel drug discovery for cell growth factor drugs, holding a globally leading position. It brings together top-tier scientific teams, undertakes major national science and technology projects, and has successfully developed a series of innovative FGF drugs with independent intellectual property rights. Through synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large‑Scale Preparation, the Center forms a complete innovation chain from source discovery and key technological breakthroughs to industrial translation. As the important R&D engine of the China Gene Valley, it continuously promotes the incubation and translation of several original new drug candidates, including a long-acting FGF21 variant. About the People's Government of Ouhai District, Wenzhou: The People's Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the "China Gene Valley," will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization. Through specialized industrial policies, "full-cycle escort" services, and clinical resource coordination, Ouhai District empowers the implementation and growth of innovation projects, serving as a vital driver for regional biomedical industry innovation and development. 30/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 30/12/2025 / 16:10 UTC+8 On December 30, 2025, the Awarding Ceremony for the 2025 ESG Value Rankings for Listed Companies, jointly organized by the Global Commercial Newspapers Union, the Hong Kong Commercial Daily, and the Hong Kong Economic Herald, was held in Hong Kong. Over a hundred guests from the Government of the Hong Kong Special Administrative Region, industry associations, listed companies, and investment institutions attended the event. Mr. Dai Jie, Managing Director of Hong Kong Commercial Daily, and Mr. Joseph Chan, Under Secretary for the Financial Services and the Treasury Bureau of the Government of the Hong Kong Special Administrative Region, were present and delivered speeches. At the ceremony, the 2025 ESG Value Rankings for Listed Companies were announced. Global New Material International (or “GNMI”) (06616.HK) stood out among the participating companies for its outstanding practices and long-term value creation capabilities in the environment, social and governance (“ESG”) fields, thereby winning the “ESG Award for Outstanding Investment Value”; Chairman and CEO Dr. Su Ertian was granted the “Award for Outstanding Impact in ESG Leadership” for his visionary leadership in sustainable development. Winning two awards in the ESG Value Rankings, setting a new benchmark for sustainable development in the new materials industryThemed “Rooted in Responsibility, Explore the Blue Ocean of Sustainable Value”, the 2025 ESG Value Rankings for Listed Companies focused on the outstanding practices of enterprises in the ESG fields, selecting outstanding enterprises and individuals who have embraced the concept of responsible development as a strategic “ballast” and an action “guiding star”. It is aimed to help enterprises build long-term competitive edges with outstanding ESG practices, navigate through cyclical fluctuations, and sail towards a broader blue ocean of sustainable value. The annual ESG Value Rankings for Listed Companies adopted an evaluation system with six key elements—strategic governance, environmental friendliness, social responsibility, value co-creation, innovation leadership, and sustainable development. Based on recommendations from the organizing committee and sponsoring institutions, scores were calculated using both objective and subjective indicators provided by shortlisted companies and professional consulting firms. Combining rigorous data analysis, company surveys, and scientific evaluation indicators, the rankings comprehensively assessed companies’ overall performance in areas such as ESG strategy integration, green technology application, achievement of emission reduction targets, promotion of social inclusion, and governance transparency. Following preliminary review of applications, data collection and research, evaluation by an expert advisory panel, and final selection by the organizing committee, the list of winners for the 2025 ESG Value Rankings for Listed Companies was finalized. GNMI (06616.HK) won two of the awards, which not only represented high praise for its deeply integrating ESG principles into core strategic operations, but also signified the capital market’s recognition of its comprehensive implementation of the ESG green development concept and its firm confidence in its inherent long-term investment value. A new pattern of sustainable growth driven by ESG initiatives As a global new materials technology platform enterprise, GNMI's core business encompasses pearlescent pigments, synthetic mica, high-end flake alumina, premium industrial functional materials, and surface-active materials. Its products are widely applied in automotive manufacturing, coatings, cosmetics, new energy, electronics, and electrical appliances. The company holds a leading global position in multiple specialized segments including pearlescent pigments, synthetic mica, and surface-active materials. In the context of global sustainable development, green manufacturing has become an inevitable choice for business development. GNMI has always adhered to the environmental philosophy of “Green Manufacturing and Eco-Enterprise”, deeply integrating the concept of high-quality, green and sustainable development into its development strategy, and actively practicing the concepts of energy conservation, emission reduction, recycling, and green development. The company saves energy at the source, controls waste in the production process, and reduces pollution at the end, striving to achieve harmless raw materials, clean production, resource utilization of waste, and low-carbon energy. The company’s environmental friendliness in its products and processes, as well as its fulfillment of social responsibility, directly impact the green transformation of downstream industries and the health and safety of end consumers. For many years, the company has built an ESG governance structure directly overseen by the board of directors, fully integrating ESG goals with R&D innovation, production operations, supply chain management, and customer service to ensure that the concept of sustainable development is adopted in every aspect of value creation. As the participating unit of the strategic emerging materials - synthetic mica project, “Strong Industrial Foundation Project”, organized by the Ministry of Industry and Information Technology in the PRC, GNMI has mastered the world’s leading and core technology for the production of pearlescent materials and synthetic mica. As of June 30, 2025, the company had 156 core patents, and more than 2,000 standard products were exported to over 150 countries and regions globally. Guangxi Chesir Pearl Material Co., Ltd., a subsidiary of the company, has been accredited as a “National Green Factory” by the Ministry of Industry and Information Technology of the PRC and a “National Intellectual Property Superior Enterprise”; and CQV, a subsidiary of the company in South Korea, has received the Gold Medal rating from EcoVadis for quite a few years in a row, acknowledging its excellence in sustainability and corporate social responsibility, thereby setting a benchmark for the industry. With the accelerated advancement of high-end production capacity layout upstream and downstream, a number of major projects have been successfully implemented. The Phase 2 Pearlescent Material Plant of Chesir Pearl has been gradually put into operation. This green production base was built by adopting globally advanced technology and the highest environmental standards. Equipped with advanced production management platform data center, it has achieved intensified, process-oriented, standardized and intelligent management. In addition, the synthetic mica project in Tonglu, Hangzhou, has entered the equipment installation phase. Leading a green revolution in the new materials industry through key technology upgradesAgainst the backdrop of global carbon neutrality goals and growing consumer awareness of environmental protection, green, safe, and traceable raw materials have become a rigid demand for downstream manufacturing industries. In particular, being “low-carbon and environmentally friendly” has become a key development trend in the pearlescent materials industry. The company holds core patents for synthetic mica manufacturing and is currently the only enterprise in the world to achieve full-category industrialization of mid- and high-end pearlescent materials such as high-performance synthetic mica-based products, flake aluminum oxide-based products, pearlescent flake-based products, and silicon dioxide-based products. It addresses the “bottleneck” challenges of depleted natural mica resources and reliance on imported high-end mica. On July 31, 2025, GNMI added another well-known brand to its portfolio by acquiring Merck’s Surface Solutions Business (SUSONITY) with €665 million. The company’s main business lines have expanded from pearlescent materials to cosmetic active materials and high-end industrial functional materials. Currently, SUSONITY maintains over 15-year partnerships with its top 10 clients, including top international clients in automobile and cosmetics industries, some of which with collaborations exceeding 30 years. This demonstrates profound brand credibility which ensures a stable presence in high-end markets. SUSONITY’s production bases in Germany, Japan and USA, combined with CHESIR and CQV manufacturing factories in China and South Korea respectively, have formed a globally integrated production network. Through acquiring SUSONITY, GNMI has obtained Merck’s global patent portfolio, proprietary formula library, and key R&D platforms in Europe, Japan and USA in the related fields. This breakthrough fully integrates the technology chain for high-end surface materials, establishing end-to-end R&D, production and commercialization capabilities from raw material development to end-use application innovation. Moving forward, the company will further integrate the worldwide sales network, broaden market coverage, enrich the product portfolio, optimize the global supply chain, and enhance the R&D capabilities. SUSONITY actively promotes responsible sourcing, running schemes of announced and un-announced audits of mines and processors, all to ensure optimal transparency in the supply chain. Meanwhile, it prioritizes sourcing programs that anticipate evolving legislation and align with the company values, and actively engages in partnerships that promote sustainable practices, improve processes and harmonize behaviors. As a co-founder of the Responsible Mica Initiative (“RMI”), the company supports the sustainable sourcing of natural mica in its supply chain. It subscribes to the 10 principles of the UN Global Compact (“UNGC”) and has incorporated these in its internal guidelines for good behaviors and practices. Rooted in responsibility, sailing towards a broader blue ocean of sustainable valueAccording to Dr. Su Ertian, the company’s leader, in an era of deep integration between technology and industry, new materials are becoming a key driving force for global sustainable development. As a pioneer in this field, GNMI is committed to empowering various industries with innovative materials and technologies and helping to build a greener, smarter, and lower-carbon future. As the chief architect of the company’s ESG strategy, and also the most active implementer and promoter of the ESG concept, Dr. Su Ertian led the relevant R&D program and invested R&D resources to promote breakthroughs in low-carbon and environmentally friendly pearlescent materials and synthetic mica technologies, ensuring that the company’s products always stay at the forefront of the industry’s green upgrades. “Rooted in Responsibility, Explore the Blue Ocean of Sustainable Value”. For GNMI, these awards represent a milestone and a new starting point. Under the leadership of Dr. Su Ertian, the company is actively leading the transformation and upgrading and the reshaping of the value chain of the global new materials industry, and is committed to creating long-term, shared, and outstanding value for shareholders, employees, customers, and the community, as it embraces the vast blue ocean of high-quality development. 30/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 30/12/2025 / 10:08 UTC+8 Starting December 22, HEYTEA and POP MART’s popular IP Twinkle Twinkle officially launched their global co-branded campaign across HEYTEA stores worldwide. Timed to the Christmas and New Year season, the collaboration is built around the theme “Twinkle Twinkle for Winter.” Centered on the warm and comforting Twinkle Twinkle characters, the campaign introduces a multi-dimensional experience that includes custom character designs, co-branded drinks, themed merchandise, themed stores, and the Inspiration Bus pop-up activation.This marks HEYTEA’s first globally synchronized co-branded launch. Even before the official rollout, the partnership generated strong attention across social platforms. With the campaign spanning Mainland China, Hong Kong SAR and Macao SAR, as well as more than 100 HEYTEA stores across the United States, the United Kingdom, Canada, and other overseas markets, the collaboration brings a shared winter moment to cities around the world.Beyond its festive appeal, the campaign offers a glimpse into HEYTEA’s approach to international markets. While character-led collaborations help create seasonal resonance, HEYTEA’s broader focus lies in building meaningful, locally grounded brand experiences that feel relevant in different cultural contexts.Localized campaigns, shaped by local cultureAcross overseas markets, HEYTEA has consistently used collaborations and pop-up activations as a way to connect with younger audiences and spark cultural conversation. Over the past year, the brand has partnered with names spanning fashion, art, and entertainment, including alexanderwang, Sandy Liang, Wicked, and Yayoi Kusama. Each collaboration is paired with limited products and immersive offline experiences, encouraging consumers to engage, explore, and share.Rather than applying a single formula across regions, HEYTEA selects creative partners with strong local or cultural relevance, develops visually distinctive concepts, and designs in-store experiences that naturally translate into social moments. This approach allows the brand to build local presence while maintaining a coherent global identity rooted in inspiration and creativity. Product creativity as a shared languageProduct creation remains central to how HEYTEA expresses its brand globally. As the originator of “new-style tea,” the brand views innovation as a way to continuously reinterpret tea culture for contemporary consumers, both in China and overseas.Internationally, HEYTEA has introduced more than 20 localized drinks designed to reflect regional taste preferences while staying true to the brand’s emphasis on natural ingredients and modern tea aesthetics. Examples include Cloud Coconut Blue, Cloud Longjing Tea Latte, and Ocean’s Glow, which incorporate lighter flavor profiles, lower sugar options, and plant-forward elements to better align with local expectations.This philosophy is reflected in the Twinkle Twinkle collaboration itself. Alongside HEYTEA’s globally available classics, the campaign introduces two exclusive drinks, Tiramisu Milk Tea and Tiramisu Rich Chocolate, marking the brand’s first globally synchronized seasonal product release. For HEYTEA, seasonal storytelling is less about promotion and more about creating moments of comfort, warmth, and shared experience across markets.The U.S. as a key stage for cultural connectionThe United States continues to play an important role in HEYTEA’s overseas presence. Since opening its first U.S. store at the end of 2023, the brand has expanded into cities including New York, Los Angeles, the San Francisco Bay Area, Houston, Seattle, and Boston. HEYTEA now operates 36 stores across the country.For HEYTEA, the appeal of the U.S. lies not only in market scale, but also in its openness to new tastes and ideas. The brand sees tea as a cultural medium, one that can create connection through shared sensory experiences. This perspective has shaped both store design and product development, encouraging exploration rather than simple adaptation.In New York’s Times Square, HEYTEA opened its overseas flagship TEA LAB store, a space designed to reinterpret Chinese tea culture through an inspiration-driven lens. Featuring exclusive drinks and a carefully curated environment, the flagship serves as a creative showcase for how tea can be experienced in a modern, global city.Supporting experiences behind the scenesAs HEYTEA expands internationally, it continues to refine the systems that support consistent experiences across markets. The brand has extended its HEYTEA GO digital platform overseas and introduced a self-operated delivery model in the U.S., helping ensure a more seamless and reliable customer journey. These behind-the-scenes capabilities allow HEYTEA to focus on what consumers see and feel, while maintaining quality and coherence across regions. About HEYTEAFounded in 2012 in Jiangmen, Guangdong, China, HEYTEA is widely recognized as the originator of new-style tea beverages. The brand created the world’s first cheese tea using real tea and real milk, setting a new standard for the industry. HEYTEA is committed to using real ingredients, including real tea, real milk, real fruit, and real sugar, while continuously reimagining tea culture through products and experiences that resonate with young consumers. Today, HEYTEA operates around 4,000 stores worldwide, including more than 100 overseas locations across Asia, North America, Europe, and Oceania.Company Name: HEYTEA Media Contact: Matthew Zhou Email（邮箱）: zhouhaoge@heytea.com Website（官网）: www.heytea.com 30/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 24/12/2025 / 09:37 MSK The leadership of Solidcore Resources plc (“Solidcore” or “the Company”) in environmental, social and governance (ESG) practices has been confirmed by the results of the S&P Global Corporate Sustainability Assessment (CSA) 2025. Solidcore’s ESG ranking in top 10% of global mining companies; Environment management system ranked in top 5% globally; Company awarded highest ranking in Kazakhstan. S&P Global completed its corporate sustainability assessment of Solidcore in December 2025. The Company ranked in the top 10% of global mining companies in the metals and mining sector, achieving a total score of 63 out of 100 (91st percentile). Solidcore also secured the highest ranking among mining and metallurgical companies in Kazakhstan. The transparency of Solidcore’s corporate disclosures and data availability was assessed as “high”. The independent evaluation by S&P Global's analysts highlights the Company’s competitive ESG positioning at both regional and international levels. S&P Global analysts especially recognised Solidcore’s achievements in environmental management. According to the assessment, the Company ranked in the top 5% of global mining companies for the quality of environmental management and the effectiveness of its environmental impact management systems, receiving an Environment score of 66 out of 100 (95th percentile). «The high scores awarded by S&P Global are the result of the systematic and day-to-day work of the entire Solidcore team, and we are rightfully proud of this recognition. At the same time, in an environment of increasingly stringent requirements and evolving non-financial reporting standards, adaptability and transparent engagement with all stakeholders remain key factors for long-term business sustainability. We are grateful to the S&P Global team for their independent and professional assessment, as well as for the opportunity to further refine our ESG strategy based on leading global best practices», – said Michael Vasilev, Head of Sustainability Reporting at Solidcore Resources plc. The CSA 2025 materials for Solidcore Resources plc are publicly available on the official S&P Global portal and may also be provided upon request by Company representatives. In addition to S&P Global’s assessment, PwC recognised Solidcore as a leader in sustainability reporting among mining and metallurgical companies in Kazakhstan under its ESG disclosure rating, published in December 2025. Solidcore received a rating of “A” (on a scale from “D” to “A+”, where “D” represents the lowest score), reflecting the quality and transparency of its ESG disclosure. About Solidcore Solidcore Resources is a leading gold producer registered in AIFC, Kazakhstan, and listed on Astana International Exchange. Solidcore operates two producing gold mines and a major growth project in Kazakhstan. About S&P Global S&P Global is a leading international analytics and ratings company providing data, research, and assessments across financial markets, sustainability, and corporate performance. The S&P Global Corporate Sustainability Assessment (CSA) is a comprehensive independent evaluation of how companies manage ESG risks and opportunities. The resulting ESG Score is based on the principle of double materiality, considering both the impact of ESG factors on a company’s competitiveness and long-term value, as well as the impact of the company’s activities on society and the environment. Enquiries Investor Relations Media Kirill Kuznetsov Alina Assanova +7 7172 47 66 55 (Kazakhstan) ir@solidcore-resources.com Yerkin Uderbay +7 7172 47 66 55 (Kazakhstan) media@solidcore-resources.kz FORWARD-LOOKING STATEMENTS This release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company’s control that could cause the actual results, performance or achievements of the company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the company’s present and future business strategies and the environment in which the company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. 24/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 23/12/2025 / 11:05 UTC+8 Sun Hung Kai & Co. Limited (“SHK & Co.”, SEHK: 86), a leading alternative investment platform headquartered in Hong Kong, announced its co-investment in a fund newly set up and managed by Trian Partners. The fund has been established to participate in an acquisition of Janus Henderson Group plc (“Janus Henderson”, NYSE: JHG), a global asset manager currently listed on the NYSE with US$484 billion in assets under management. Further details are available in SHK & Co.’s official announcement. Under a definitive agreement, Janus Henderson will be acquired by Trian Fund Management, L.P. and its affiliated funds (“Trian”), and General Catalyst Group Management, LLC and its affiliated funds (“General Catalyst”) in an all-cash transaction at an equity value of approximately US$7.4 billion. For more information, please refer to the official press release. Trian, an investment firm with significant experience investing and operating in the asset management sector, currently owns 20.6% of Janus Henderson’s outstanding shares and has been a shareholder since 2020 with Board representation since 2022. General Catalyst is a global investment and transformation company with a focus on applying AI to enhance business operations. As a private company, Janus Henderson would continue to be led by the current management team with Ali Dibadj as Chief Executive Officer and would maintain its main presence in both London, England, and Denver, Colorado. Tony Edwards, Deputy CEO at SHK & Co., commented: “SHK & Co. is pleased to participate in the co-investment in Janus Henderson, a leading global active asset manager with a 91-year heritage. We have been impressed by the company’s outstanding performance under the leadership of Ali and his exceptional team. By partnering with Trian, General Catalyst, and fellow investors, we see significant potential for Janus Henderson to enhance its product offerings, client services, technology, and talent development. SHK & Co. remains committed to strengthening our alternative investment platform through strategic investments and long-term global partnerships. We believe this investment will further advance our ability to deliver innovative solutions for our clients and support our platform’s growth.” The investor group includes strategic investors SHK & Co., Qatar Investment Authority, and other global investors such as MassMutual, all of whom are excited to partner with Janus Henderson, its employees, and clients. - End - About Sun Hung Kai & Co. Sun Hung Kai & Co. Limited (SEHK: 86) (“SHK & Co.” / the “Company”, together with its subsidiaries, the “Group”) is a leading Hong Kong-based financial institution recognised for its expertise in alternative investments and wealth management. Since 1969, the Company has built a diversified investment portfolio across public markets, credit and alternatives strategies including real estate and private equity, delivering long-term risk-adjusted returns. Leveraging on its deep-rooted Asian heritage, SHK & Co. supports and nurtures specialist emerging asset managers globally, empowering them to excel. SHK & Co. also utilises its long-standing investment expertise and resources in providing tailored investment solutions to like-minded partners and ultra-high-net-worth investors through its Family Office Solutions. As at 30 June 2025, the Group held about HK$37.7 billion in total assets. For more, please visit: www.shkco.com / follow SHK & Co. on LinkedIn. About Janus Henderson Group plc Janus Henderson Group is a leading global active asset manager dedicated to helping clients define and achieve superior financial outcomes through differentiated insights, disciplined investments, and world-class service. As of September 30, 2025, Janus Henderson had approximately US$484 billion in assets under management, more than 2,000 employees, and offices in 25 cities worldwide. The firm helps millions of people globally invest in a brighter future together. Headquartered in London, Janus Henderson is listed on the New York Stock Exchange. About Trian Fund Management Founded in 2005, Trian Fund Management, L.P. (“Trian”) is a multi-billion dollar investment management firm. Trian is a highly engaged shareholder, bringing an entrepreneurial spirit, deep operational expertise, and an ownership mentality to its public and private investments. Leveraging the 50+ years’ operating experience of our Founding Partners, Nelson Peltz and Peter May, Trian seeks to invest in high quality companies with untapped potential. Trian works with management teams and boards to help companies execute operational and strategic initiatives designed to drive long-term shareholder value. For more: www.trianpartners.com. About General Catalyst General Catalyst is a global investment and transformation company that partners with the world’s most ambitious entrepreneurs to drive resilience and applied AI. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond. With offices in San Francisco, New York City, Boston, Berlin, Bangalore, and London, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Applied Intuition, Commure, Glean, Guild, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto. For more: www.generalcatalyst.com. Media enquiry, please contact: Burson Sidney Leng +852 5443 4320 Caleb Leung +852 9190 1969 Joyce Zhan +852 9142 2528 Email: SHKCo@hkstrategies.com 23/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 22/12/2025 / 09:10 MSK Solidcore Resources plc (“Solidcore” or the “Company”) announces that the mandatory buyback of shares held under Euroclear has been completed. “I am pleased to confirm the successful completion of the mandatory buyback of the remaining blocked shares. This important milestone strengthens our corporate governance, enhances transparency, and supports further strategic developments focused on shareholder value recovery”, said Vitaly Nesis, CEO of Solidcore Resources plc. Following the issuance of the Restriction Notice on 4 December 2025, the Company has completed the repurchase of 123,408,853 shares (the “Restricted Shares”) under the Restricted Share Buyback Agreement with Euroclear, and paid the total buyback consideration of AED 288,337,115.84 (“Total Purchase Price”) to a bank account managed by a professional trustee for the benefit of Euroclear. Accordingly, the Restricted Shares qualify as treasury shares and are blocked by the Company’s registrar. The Total Purchase Price was calculated based on 30,544,186 non-treasury shares held through Euroclear and a price per share of US$ 2.57 (“Purchase Price”) converted into AED at an exchange rate of 3.6725[1] AED per one USD. No consideration was paid in respect of those Restricted Shares which are already held on behalf of the Company through Euroclear (i.e., 92,864,667 shares). Pursuant to the Restricted Share Buyback Agreement and the process approved by shareholders at the general meeting on 29 July 2025, Euroclear is entitled to apply to the trustee for a payment of the Total Purchase Price (or any portion thereof) provided only when Euroclear: certifies to the trustee that the payment to Euroclear of the Total Purchase Price (or a respective portion thereof) in consideration for the transfer of the legal title to the Restricted Shares (or a respective portion thereof) and the reconciliation of Euroclear's books and records to reflect such transfer, is lawful under any sanctions which are applicable to Euroclear; undertakes to instruct the Company’s registrar to transfer the Restricted Shares (or any portion thereof) to the Company’s account in the share registry maintained by the registrar, and to reconcile its records to reflect the transfer of a relevant amount of the Restricted Shares to the Company and provides satisfactory evidence of this to the trustee; undertakes to distribute the Total Purchase Price (or a respective portion thereof) to Euroclear's direct participants in discharge of such participants’ book-entry interests in the Restricted Shares; and submits any additional information or documentation the trustee deems necessary to process the payment. Any person with an entitlement to Restricted Shares repurchased from Euroclear should consult with their broker, custodian or depositary through which such entitlement derives in order to claim its interest in any relevant funds from Euroclear. Following the mandatory buyback, the Company holds 123,408,853 shares in treasury, and the total number of shares with voting rights in the Company is 443,146,134. The latter number may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest (or a change therein) in Solidcore under the Rule MDR 3.3 of the AIX Market Disclosure Rules. Unless otherwise defined herein, defined terms have the same meaning as those attributed to them in the Circular: https://www.solidcore-resources.com/en/investors-and-media/shareholder-centre/general-meetings/. About Solidcore Solidcore Resources is a leading gold producer registered in AIFC, Kazakhstan, and listed on Astana International Exchange. Solidcore operates two producing gold mines and a major growth project in Kazakhstan. Enquiries Investor Relations Media Kirill Kuznetsov Alina Assanova +7 7172 47 66 55 (Kazakhstan) ir@solidcore-resources.com Yerkin Uderbay +7 7172 47 66 55 (Kazakhstan) media@solidcore-resources.kz DISCLAIMER This release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company’s control that could cause the actual results, performance or achievements of the company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the company’s present and future business strategies and the environment in which the company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Astana International Exchange Ltd and its affiliates assume no responsibility for the contents of this announcement, the decision of the Company to proceed with the mandatory buyback, or the terms, mechanics, or consequences of such buyback. Neither AIX nor its affiliates has reviewed or approved the substance of the transaction described herein, expresses any view on its merits, or accepts any liability for any loss or damage arising from, or in connection with, this announcement, the mandatory buyback, or any related corporate actions. The Company remains solely responsible for the accuracy, completeness and fairness of the information contained in this announcement and for ensuring compliance with all applicable laws, regulations, and corporate governance requirements. [1] According to the rate published by the Central Bank of the UAE as of 18 December 2025. 22/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 19/12/2025 / 10:00 UTC+8 Dubai, UAE - December 19, 2025 - (SeaPRwire) - Kamil Magomedov, an investment-focused real estate broker at Provident Estate, has released a new market outlook analyzing Dubai’s next phase of residential development, identifying Expo City Dubai, Dubai Islands, and the Dubai Water Canal corridor as emerging growth areas shaped by long-term master planning and infrastructure expansion. Dubai broker Kamil Magomedov anticipates demand, guiding investors to strategic properties by analyzing city master plans. His methods set him apart among industry peers as he prioritizes long-term residential gains and connects investor goals with urban growth and future infrastructure enhancements. Photo Courtesy of Kamil Magomedov Kamil Magomedov, a leading real estate expert and broker based in Dubai, is helping investors succeed by applying deep knowledge from city-building and investment strategy. While many brokers respond to press releases, Magomedov studies Dubai’s master plans to spot high-growth opportunities before they enter mainstream conversations. With years of experience as the former head of a government agency for investment development in Russia and as a national project leader responsible for the master plan of a city for 300,000 residents, Magomedov finds potential where others see untouched land. “When you’ve been on the side designing a city, you look at Dubai very differently. You see the logic before the buildings appear, the footfall, the infrastructure, the lifestyle ecosystem that will shape value,” says Magomedov. A recent example is Expo City Dubai. When His Highness Sheikh Mohammed bin Rashid Al Maktoum approved its master plan, much of the market doubted the future of the former Expo 2020 site. Magomedov, however, recognized a blueprint for one of Dubai’s most important future growth centers. He promptly informed his investor base and guided purchases in top locations near the entrance to the exhibition centre, areas mostly overlooked by agents. When major events and the World Trade Center relocate to Expo City by late 2026, the demand for residential units will significantly outnumber available options. This creates an opportunity for strong rental yields for Magomedov’s early-entry investors. “We entered early. By the time others realised why Expo City mattered, our investors were already holding the prime inventory, properties that will deliver 15–18 percent rental yields once events move in,” he says. Magomedov uses the same strategy on Dubai Islands along the waterfront. Here, he advises investors on Mr Eight, Rixos Residences, Imtiaz Beachwalk 1 & 3, and Grande, which offer daily amenities for residents, not just visitors. He notes, “Beach-access homes built for residents are in massive scarcity. Most beach projects were made for short stays. Dubai Islands change that, it brings everyday infrastructure to the shoreline.” Choosing highly walkable micro-zones on the islands, in his view, supports long-term value and rental performance. Further north along Dubai Water Canal, Magomedov sees the start of what will be Dubai’s “Mayfair or Fifth Avenue,” where prestigious properties like Muraba Veil and The Rings by PMR set new benchmarks for luxury living. “Not many understand that each city has the most valuable strip of land with the most valuable projects, and in Dubai that place is just emerging,” he notes. Magomedov continues to put his clients in properties along the Canal, suited to lasting value rather than fast turnover. Magomedov approaches real estate through the lens of urban logic rather than only numbers. While many agents focus on price per square foot, he considers the future residents, how infrastructure will support them, and demographic and visitor projections to calculate long-term value. “The average broker looks at today’s floor plan. I look at tomorrow’s skyline. Because I’ve built cities, I know how cities grow,” Magomedov says. This way of working, shaped by practical experience in planning and investment, has resulted in some of Dubai’s most lucrative property deals, often completed quietly, but noticeable in market results. His formula for success stays simple: Read the master plan, not the marketing brochure; invest before a location is accepted by the wider market, especially in places others doubt but where planning provides a future; and choose homes based on what future residents will want, not just what is currently popular. This lets Magomedov consistently “see the city before it’s built.” Dubai’s investor mix is also seeing change. Magomedov remarks on the movement from quick-flip buyers to thoughtful, rational buyers, including family offices and European investors from the UK, Germany, Italy, and the Netherlands. “They want to know exactly what they’re paying for, why, and how that property fits the city’s long-term direction. That’s why the master-plan approach resonates,” Magomedov explains. Magomedov believes Dubai’s next in-demand areas will be those where long-term livability meets liquidity. He adds, “The smart investor today buys into the city of tomorrow. That means choosing projects that make sense ten years from now, not ten weeks,” he says. With over twelve years spent in leadership and urban planning, Kamil Magomedov’s property market analysis is widely followed for translating complex city plans into practical investment moves. His YouTube channel offers steady guidance for investors exploring Dubai’s emerging areas such as Expo City, Dubai Islands, and Dubai Water Canal, and has grown into a widely-trusted resource for understanding the city’s property market. Kamil Magomedov is investment-focused real estate broker at Provident Estate in Dubai. He specializes in guiding international investors, offering strategic property solutions across residential, commercial, and luxury segments while drawing on a strong background in city planning and investment management. Media Contact Company: Provident Estate Contact: Kamil Magomedov Telephone: +971501610143 Email: kamil@providentestate.com Website: https://providentestate.com 19/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 17/12/2025 / 14:00 UTC+8 Berlin, Germany - December 17, 2025 - (SeaPRwire) - HIKMICRO has launched the HABROK 4K 2.0, an all-in-one digital hunting device designed to provide hunters with advanced observational capabilities. Integrating thermal and full-color CMOS technologies in a single portable unit, HABROK 4K 2.0 delivers clear identification in daylight, twilight, and complete darkness, offering a versatile solution for modern hunting challenges. The device builds on the success of HIKMICRO’s 2024 HABROK 4K, combining real-world hunter feedback with technological enhancements to create an intuitive, one-handed experience. Its design mirrors traditional binocular ergonomics, allowing hunters to adapt quickly to the device while accessing advanced viewing and targeting features. Introducing HABROK 4K 2.0: Advanced All-in-One Hunting Optics HABROK 4K 2.0 integrates thermal imaging, full-color CMOS viewing, and infrared night vision into a single compact unit. This all-in-one approach enables hunters to detect heat signatures, identify targets in full color, and maintain visibility in complete darkness, all without needing to switch devices. The ergonomic design supports mobility and ease of use, closely resembling the handling of traditional binoculars. The device represents HIKMICRO’s ongoing commitment to digital hunting innovation, combining technological refinement with feedback from experienced hunters to meet real-world needs. Seamless Viewing and User-Friendly Controls The HABROK 4K 2.0 features a rear focus wheel positioned closer to the eyepiece, allowing for rapid and precise adjustments with minimal hand movement. A fast Thermal/Digital switch allows hunters to transition smoothly between viewing modes, improving response time and observation efficiency. Image stabilization and adjustable magnification across both thermal and digital channels ensure clear, steady views at varying distances. The shutterless

EQS via SeaPRwire.com / 17/12/2025 / 12:00 UTC+8 Berlin, Germany - December 17, 2025 - (SeaPRwire) - HIKMICRO has announced the launch of its HABROK 4K 2.0, the latest evolution of its all-in-one digital hunting device. Designed to combine advanced thermal imaging, full-color optics, and infrared night vision in a single, portable unit, HABROK 4K 2.0 represents the company's continued effort to enhance observation tools for hunters. Building on the foundation set by the original HABROK 4K, released in 2024, HABROK 4K 2.0 integrates technology and real-world user feedback to offer hunters a more intuitive and precise viewing experience. The device enables quick detection of heat signatures, clear identification in various lighting conditions, and seamless operation that supports intuitive field use. HIKMICRO's HABROK 4K 2.0 introduces multiple enhancements designed to optimize clarity, control, and comfort for hunters. A rear focus wheel, positioned close to the eyepiece, provides fast and familiar adjustment, while a new Thermal/Digital switch enables users to transition instantly between heat detection and detailed full-color or infrared views. These features support single-handed operation, allowing the other hand to be free for managing hunting equipment. HIKMICRO's HABROK 4K 2.0 introduces multiple enhancements designed to optimize clarity, control, and comfort for hunters. A rear focus wheel, positioned close to the eyepiece, provides fast and familiar adjustment, while a new Thermal/Digital switch enables users to transition instantly between heat detection and detailed full-color or infrared views. These features support single-handed operation, allowing the other hand to be free for managing hunting equipment. Additional technological upgrades include an image stabilization algorithm and adjustable magnification across thermal and digital channels, ensuring steady visuals from wide-area scans to precise close-ups. The device also incorporates shutterless technology for the

EQS via SeaPRwire.com / 17/12/2025 / 10:02 UTC+8 Berlin, Germany - December 17, 2025 - (SeaPRwire) - HIKMICRO introduced the HABROK 4K 2.0 to provide high-performance observational tools for hunters, wildlife enthusiasts, and outdoor professionals. This handheld multi-spectrum binocular delivers clear, high-resolution imaging across a wide range of lighting conditions. Integrating thermal imaging, 4K digital optics, and a laser rangefinder into a compact binocular-style body, the HABROK 4K 2.0 improves field awareness, environmental assessment, and wildlife monitoring. Developed as the second generation of the HABROK 4K series, the HABROK 4K 2.0 builds upon the strengths of its predecessor while incorporating user feedback to enhance real-world usability. Its multi-spectrum imaging system overlays a sensitive thermal detector onto a 4K ultra-high-definition digital channel. This setup allows users to detect heat signatures, identify environmental details, and maintain visibility in low-light, shadowed, or partially obstructed conditions. The dual-channel design helps users switch smoothly between thermal and digital imagery throughout the day and night. Ergonomic Design for Extended Use The binocular's design accommodates users who spend long periods in the field. The compact housing balances naturally in the hands, reducing fatigue during extended scanning or methodical observation. Key controls sit within reach for one-handed operation, leaving the other hand free for navigating terrain or stabilizing movement. A rear focus wheel provides quick, tactile adjustment, while the integrated mode switch allows seamless transitions between thermal, digital, and infrared-assisted night views. Enhanced Stability and Continuous Imaging Digital stabilization reduces image shake during handheld use, which is particularly helpful when observing from uneven ground, in cold conditions, or over prolonged sessions. Shutterless thermal calibration enables continuous imaging, eliminating the pauses typically associated with traditional thermal devices. Users can track animal movement, environmental activity, and terrain changes without interruption. Integrated Distance Measurement The built-in laser rangefinder delivers accurate distance readings to support situational awareness, environmental assessment, and route planning. It helps users gauge the location of wildlife, landmarks, or terrain features relative to their position. The HABROK 4K 2.0 functions solely as an observational device, providing clear imaging and enhanced visibility without supporting shooting or targeting activities. "HABROK 4K 2.0 reflects our focus on practical and dependable tools for outdoor users," said [HIKMICRO spokesperson]. "Combining advanced imaging technologies with a familiar binocular-style layout helps users maintain clear visibility across varied environments and lighting conditions." The HABROK 4K 2.0 is available through authorized HIKMICRO dealers. For more information, visit the HIKMICRO website. About HIKMICRO HIKMICRO is a global leader in thermal imaging and optical technologies, offering effective solutions for professional and recreational applications. The company provides high-performance, user-friendly devices that support observation, safety, and environmental awareness. Contact Information Brand: HIKMICRO Contact: Lina Wang Email: wanglina21@hikmicrotech.com Website: https://www.hikmicrotech.com/en/ 17/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 11/12/2025 / 17:30 UTC+8 Town Health Charity Foundation Donates 20-valent Pneumococcal Conjugate Vaccines TWGHs Collaborates on Community Vaccination (Hong Kong, 11 December, 2025) Town Health International Medical Group Limited (“Town Health”) has partnered with Pfizer Corporation Hong Kong Limited (“Pfizer”) to promote territory-wide respiratory health education. Town Health announced today that, through the Town Health Charity Foundation, it is donating a batch of 20‑valent pneumococcal conjugate vaccine (“PCV20”) (Manufacturer: Pfizer) to Tung Wah Group of Hospitals (“TWGHs”) to support vulnerable groups, strengthening medical–social collaboration to enhance community health protection. Town Health and Pfizer are actively responding to the Primary Healthcare Blueprint of the Hong Kong Health Bureau and are launching a territory‑wide respiratory health education initiative jointly to promote a shift in the public’s mindset from “treatment-based” to “prevention-oriented”. Meanwhile, Town Health will leverage its extensive network of medical centres across Hong Kong to facilitate the public access to protection through PCV20. As a key community partner, TWGHs will oversee proper allocation of the PCV20 donated by the Town Health Charity Foundation and identify suitable beneficiaries across its service units for vaccination. Town Health, Pfizer and TWGHs will continue to work closely together to uphold Town Health Charity Foundation’s vision of “Guided by Love, Advancing Health for All”—to reduce the disease burden among underserved groups and enhance the overall health of the community. Photo caption: Mr. Karson Choi Ka Tsan, GBS, JP, Chairman and CEO of Town Health (center), Dr. Alan Koo Chung Wai, Vice Medical Director of Town Health (third right), Mr. Huang Yu, Executive Director of Town Health (second right), Ms. Zhang Xiaoxue, Executive Director of Town Health (first right), Mr. Thomas Chan Chun Hong, COO of Town Health (first left), Dr. Wong Kam Cheung, Specialist in Respiratory Medicine (third left), Mr. Nicholas Chan, Commercial Lead of Pfizer Hong Kong and Macau (fourth right), Mr. Albert Kwong, Strategic Healthcare Partner, Cross Business Units of Pfizer Hong Kong and Macau (second left), and Dr. Chan Lee, Head of TWGHs K B Tam & W K Li Medical Centre (North Point) (fourth left) attended the vaccine donation ceremony together to jointly promote preventive health for all and build a safer community. ~ Cont. ~ Mr. Karson Choi Ka Tsan, GBS, JP, Chairman and CEO of Town Health, said that pneumococcal infections pose a significant public health threat in Hong Kong, particularly to the elderly and vulnerable groups, making public education on respiratory health an urgent priority. To this end, Town Health has introduced the PCV20, allowing the public to obtain broad protection against 20 Streptococcus pneumoniae serotypes with just a single dose. He added that through Town Health Charity Foundation’s donation of vaccines to TWGHs, Town Health is taking concrete action to support vulnerable groups through medical–social collaboration. Mr. Nicholas Chan, Commercial Lead of Pfizer Hong Kong and Macau, shared the view and emphasised that pneumococcal disease places a significant healthcare burden for Hong Kong society and believes that comprehensive Streptococcus pneumoniae serotype protection is essential. He hopes that this collaboration will enhance public understanding of pneumococcal disease. Dr. Chan Lee, Head of TWGHs K B Tam & W K Li Medical Centre (North Point), expressed gratitude to Town Health and Pfizer for their commitment to community health and TWGHs is honoured to serve as a community partner and is committed to the proper utilisation of the vaccines donated by the Town Health Charity Foundation to effectively support vulnerable groups in need. Dr. Alan Koo Chung Wai, Vice Medical Director of Town Health, reminded the public not to underestimate the threat of pneumonia. Dr. Koo noted that, according to the latest statistics from the Department of Health, pneumonia is the second leading cause of death in Hong Kong. In 2024, pneumonia caused more than 11,000 deaths, second only to cancer and surpassing heart disease and cerebrovascular disease¹. Streptococcus pneumoniae is a common cause of pneumonia, and over 100 serotypes have been identified². Vaccination is one of the most effective means of preventing pneumococcal disease. Dr. Wong Kam Cheung, Specialist in Respiratory Medicine, explained that pneumococci spreads through droplets or contact and has a short incubation period of around one to three days³. Early symptoms of pneumococcal pneumonia such as fever and cough often resemble influenza, leading to misdiagnosis. Co‑infection with influenza may also occur, increasing complexity in diagnostic and treatment. While pneumococci may cause milder illnesses such as otitis media or sinusitis, in high‑risk individuals it can lead to severe diseases such as invasive pneumonia, bacteraemia, sepsis, and meningitis3,4,5, with rapid deterioration that may be life‑threatening. Vaccination remains the most effective preventive measure which can significantly reduce the risk of invasive infections and severe outcomes3,4,5, and studies also show that it may lower the risk of heart attacks among high‑risk individuals⁶. Although antibiotics are the mainstream of treatment, antibiotic resistance made therapy increasing difficult³. Dr. Wong reiterated that “prevention takes precedence over treatment”, particularly in addressing pneumococcal infections. For details on the indications and usage of pneumococcal conjugate vaccines, please consult your doctor. ~ Ends ~ About Town Health: Build Healthier Life and A Better Tomorrow Town Health International Medical Group Limited (Stock Code: 3886.HK) is one of the largest listed healthcare groups with the longest history in Hong Kong and it is one of the few local comprehensive medical institutions that provides healthcare services in both Hong Kong and the Mainland China. The Group boasts high-quality medical resources and a strong professional medical team. Its business segments include: (i) The provision of medical services in Hong Kong; (ii) The provision of medical network management business in Hong Kong; (iii) The provision of hospital management and health management businesses in the Mainland China; and (iv) The provision of aesthetic medical and beauty and wellness services in Hong Kong and the Mainland China. The Group is committed to become an international first-class medical group rooted in Hong Kong, covering Greater Bay Area and serving the whole country, and is dedicated to build healthier life and a better tomorrow. To learn more, please visit us on https://thmd.townhealth.com and follow us on https://www.facebook.com/TownHealthMedicalHK. About Town Health Charity Foundation: Concerns The Needs of Society Town Health takes “Corporate Social Responsibility” as an important developing direction with the aim of being responsible for the stakeholders, the community and the environment. These years, Town Health has supported the local charity organisations in various ways and has delivered various support services to the vulnerable community. Up to now, the Group is being acknowledged by HKCSS as “Caring Company” in consecutive years. On 8 October 2015, the Group sets up Town Health Charity Foundation and takes “Supporting Underprivileged” and “Promoting Healthy Lifestyle” as main direction. The Foundation hopes to provide funding for local NGOs and allow them to deliver social services to the needy. About Tung Wah Group of Hospitals: Tung Wah Group of Hospitals, founded in 1870, is the oldest and well-established charitable organisation in Hong Kong. The Group is providing medical, educational, community and traditional services with the mission of “healing the sick and relieving the distressed, caring for the elderly and rehabilitating the disabled, promoting education and nurturing the youngsters, and raising the infant and guiding the youth”. Regarding the medical and health services, Tung Wah Group manages 5 hospitals (Tung Wah Hospital, Kwong Wah Hospital, Tung Wah Eastern Hospital, TWGHs Wong Tai Sin Hospital and TWGHs Fung Yiu King Hospital.), 42 Chinese and Western medicine services units and 1 community pharmacy, which provide Chinese and western medicine services, screening, computed tomography, dental and elderly health services. Tung Wah Group endeavors to develop its medical and health services to meet with the needs of the community. It has also established various patient assistance programmes to provide subsidy to needy people to facilitate them receiving medical services, with the aim to promote public health. For further information of Tung Wah Group, please visit www.tungwah.org.hk. About Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.pfizer.com.hk and like us on YouTube at www.youtube.com/c/pfizerhongkong. About 20-valent pneumococcal conjugate vaccine (PCV20): PCV20 is Pfizer’s next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) already included in Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. The vaccine also contains capsular polysaccharide conjugates for seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease, and have been associated with high case-fatality rates, antibiotic resistance, and/or meningitis. PCV20 contains the broadest serotype coverage of any available pneumococcal conjugate vaccine and helps combat against the 20 Streptococcus pneumoniae serotypes in the vaccine. High-risk groups for pneumococcal infections include3,4,5: Children Elderly Others: History of invasive pneumococcal disease, cerebrospinal fluid leakage or cochlear implant; Chronic cardiovascular (except hypertension without complication), lung, liver or kidney diseases; Metabolic diseases including diabetes mellitus or obesity (Body Mass Index 30 or above); Immunocompromised states related to weakened immune system due to conditions such as asplenia, HIV/AIDS or cancer/steroid treatment; and Chronic neurological conditions that can compromise respiratory functions, the handling of respiratory secretions, increase the risk for aspiration or those who lack the ability to take care of themselves. Centre for Health Protection. Number of Registered Deaths by Leading Cause of Death, 2001-2024. https://www.chp.gov.hk/tc/statistics/data/10/27/380.html Bertran, Marta et al (2024, March 27). Invasive pneumococcal disease 3 years after introduction of a reduced 1+1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study, The Lancet Infectious Diseases, Volume 24, Issue 5, 546 – 556. Centre for Health Protection. Pneumococcal Infection. https://www.chp.gov.hk/en/healthtopics/content/24/10584.html U.S. Centers for Disease Control and Prevention. Pneumococcal Disease. https://www.cdc.gov/pneumococcal/index.html Centre for Health Protection. Pneumococcal Vaccination. https://www.chp.gov.hk/en/features/108124.html Bettina Heidecker, Peter Libby, Vassilios S Vassiliou, François Roubille, Orly Vardeny, Christian Hassager, Michael A Gatzoulis, Mamas A Mamas, Leslie T Cooper, Felix Schoenrath, Marco Metra, Offer Amir, Scott D Solomon, Ulf Landmesser, Thomas F Lüscher. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement: With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute Cardio Vascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 46, Issue 36, 21 September 2025, Pages 3518–3531. https://doi.org/10.1093/eurheartj/ehaf384 11/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 10/12/2025 / 16:39 UTC+8 On 25 November 2025, ActusRayPartners won two prestigious awards at the HFM European Performance Awards 2025: 1) “European equity”, and 2) “Market-neutral”. These two accolades recognize the outstanding performance of the ActusRayPartners European Alpha Fund from 1 July 2022 to 30 June 2025. ActusRayPartners is a quantitatively oriented but ultimately discretionary hedge fund manager seeded and supported by Sun Hung Kai Capital Partners, the funds management platform of Sun Hung Kai & Co. Limited (“SHK & Co.”, SEHK: 86). Established in 2019, ActusRayPartners has achieved significant growth, with its assets under management (AUM) increasing over 100 times to surpass US$2 billion as of 30 November 2025. As equity markets advanced over the performance assessment period, it is a significant achievement that ActusRayPartners’ equity market-neutral work (which carries near-zero beta) was strong enough to win against both equity long-short (which often carries approximately 50% beta) and equity market-neutral peers in the same evaluation window. Since the “Market-neutral” category was introduced at the HFM European Performance Awards, no other hedge fund manager has won both best equity long-short and best equity market-neutral in the same year. Additionally, no other Asia-based manager has won either of these two categories for, at least, the past decade+. “As a Hong Kong-headquartered asset management company, we are proud that our European strategy has been consistently recognised since its inception in March 2021, including winning an award in each of the past three years. We believe these awards reflect the strength of our Discretionary Probabilistic Investing process and the dedication of our team,” said the Co-Founders of ActusRayPartners. Tony Edwards, Executive Director and Deputy CEO of SHK & Co., commented: “Congratulations to the ActusRayPartners team on their remarkable double win at the HFM Performance Awards! To win in both the Equity Market-Neutral and Equity Long-Short categories is a significant achievement and a testament to their expertise and disciplined strategy. As a long-term seeding partner, we take great pride in their tremendous growth since our collaboration began five years ago. At SHK & Co., we remain dedicated to support and empower specialist emerging asset managers across Asia, helping them thrive in dynamic markets. ActusRayPartners exemplifies this partnership and commitment.” The HFM European Performance Awards is highly regarded in the hedge fund industry, honouring excellence in various categories such as fund performance, operational capabilities, and service providers. Organized by HFM Global, a leading source of hedge fund intelligence, these awards have a long history of celebrating firms that demonstrate exceptional performance and innovation. – End – About ActusRayPartners ActusRayPartners is a Hong Kong-headquartered asset management company equally co-founded by Andrew Alexander, Raymond Chan, and Patrick Cheung in 2019. Several members of the team previously worked together in the Quantitative Hedge Funds division of Macquarie Group. Today, ActusRayPartners comprises 36 members across Hong Kong and Sydney, managing over US$2 billion (as of 30 November 2025) across Europe and Asia. ActusRayPartners employs a Discretionary Probabilistic Investing process which is a synthesis of: (1) a quantitative base, and (2) discretionary adjustments to address quantitative deficiencies. The quantitative base uses fundamental, sentiment, technical and alternative data, and employs advanced statistics, natural language processing, and artificial intelligence techniques. The discretionary work focuses on addressing challenges with purely systematic processes and is not fundamental, macro or flow driven. ActusRayPartners is licensed by the Hong Kong Securities and Futures Commission (Type 4 “Advising on Securities” and Type 9 “Asset Management” license) and is a Registered Investment Adviser with the U.S. Securities and Exchange Commission and has not yet made an application to be licensed in any other jurisdiction. About Sun Hung Kai & Co. and Sun Hung Kai Capital Partners Sun Hung Kai & Co. Limited (SEHK: 86) (“SHK & Co.” / the “Company”, together with its subsidiaries, the “Group”) is a leading Hong Kong-based financial institution recognised for its expertise in alternative investments and wealth management. Since 1969, the Company has built a diversified investment portfolio across public markets, credit and alternatives strategies including real estate and private equity, delivering long-term risk-adjusted returns. Leveraging on its deep-rooted Asian heritage, SHK & Co. supports and nurtures specialist emerging asset managers in the region, empowering them to excel. SHK & Co. also utilises its long-standing investment expertise and resources in providing tailored investment solutions to like-minded partners and ultra-high-net-worth investors through its Family Office Solutions. As at 30 June 2025, the Group held about HK$37.7 billion in total assets. For more information, please visit: www.shkco.com / follow SHK & Co. on LinkedIn. Founded in 2020, Sun Hung Kai Capital Partners Limited (“SHKCP”) is a Hong Kong SFC regulated subsidiary of SHK & Co., with Type 1, 4 and 9 licenses. For more information, please visit: www.shkcapital.com / follow SHKCP on LinkedIn. For media enquiries, please contact: Burson Sidney Leng +852 5443 4320 Caleb Leung +852 9190 1969 Joyce Zhan +852 9142 2528 Email: SHKCo@hkstrategies.com 10/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 10/12/2025 / 15:59 UTC+8 Muscat, Oman - December 10, 2025 - (SeaPRwire) - Beyond ONE shares a surge in Oman's digital payments sector following the launch of its platform, Friendi Pay. The digital service, rolled out in May 2025, has spurred a 600% in digital payments and more than 800% growth in international remittances. Additionally, within this short timeframe, Friendi Pay has seen monthly transaction volumes expand from thousands to tens of thousands, with the value of domestic transfers climbing by over 360% to nearly one million Omani rials. The platform's onboarding rate has also improved by 55%, signaling a shift in how Omani residents and expatriates manage their finances both at home and abroad, and demonstrating the widespread appeal of trustworthy, transparent, and easy-to-use digital finance solutions. Human-Centric Design And Commitment To Trust Friendi Pay is anchored in the understanding that trust is the cornerstone of advancement in financial technology. Every transaction is safeguarded by comprehensive Know Your Customer (KYC) and Anti-Money Laundering (AML) protocols, with continuous collaboration alongside the Central Bank of Oman to ensure payments consistently meet the nation's highest security standards. "Families deserve clarity upfront and transparency at every stage. We show the full cost and let every user track their transaction step by step," Tawfiq Al Lawati, CEO of Friendi Pay Oman, mentions. Beyond security infrastructure, Friendi Pay delivers accessibility through design. The platform operates with WhatsApp-first support and a user interface available in five languages: Arabic, English, Hindi, Bengali, and Tagalog, enabling onboarding, inquiries, and assistance through real-time, multilingual communication channels. Rooted in the behavioral habits of over one million Friendi Mobile users, the platform integrates seamlessly with diverse lifestyles, meeting people "where they are" and addressing the everyday financial needs of local families and expatriates alike. From utility bill payments and in-store purchases to remittances and peer-to-peer transfers, Friendi Pay seamlessly integrates digital finance into daily life. Hani ELKukhun, CEO of Middle East at Beyond ONE, states, "We are not just simplifying transactions, we are humanizing finance for real lives and real communities." Responsible Innovation In A Rapidly Growing Market Amid forecasts that Oman's digital payments sector will exceed $20.8 billion by 2029, Friendi Pay sets the standard for responsible, compliance-oriented fintech development. Every new feature and payment corridor undergoes rigorous internal and regulatory scrutiny before launch. Transparent fee structures, real-time transaction visibility, and accessible support empower users to navigate a market that is becoming more competitive and consumer-centric by the day. The ripple effect is greater consumer literacy, informed comparisons between services, and accountability-driven competition. In doing so, Friendi Pay is disrupting the market while proving that profitability and principle can coexist in the same product. Available on both the Apple App Store and Google Play, Friendi Pay is open to all residents of Oman. Its journey in the fintech space has just begun, but the platform is committed to supporting real household needs, driving financial inclusion, and aligning the country's vision for a stronger digital financial economy. "As Oman moves toward Vision 2040 and a diversified digital economy, Friendi Pay will deliver ever more local payment solutions, open fresh remittance corridors, and set new standards for customer experience," mentions Al Lawati. "Progress happens when fintech listens to real people. That's how we ensure growth is responsible, sustainable, and empowering, at scale." About Beyond ONE Beyond ONE is a global digital services aggregator founded in 2021 and headquartered in Dubai, with a strong presence in Latin America and the Middle East. Their mission is to simplify people's lives by delivering the right services, at the right time, for the right reason, to the right people, all in one trusted place. Contact Details Brand: Beyond ONE Contact: Ahmed Ibrahim, Director of PR and Social Media Email: ahmed.ibrahim@beyond.one Website: https://beyond.one 10/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com